There are multiple TEADi currently in Phase I human clinical trials for NF2-deficient mesotheliomas that target the highly-conserved central palmitate binding pocket, including VT3989 from Vivace Therapeutics (NCT04665206)86. The gene discussed is NF2; the disease is mesothelioma.